Samsara Bio Capital, LLC Rain Therapeutics Inc. Transaction History

Samsara Bio Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.09 - $9.93 $246,449 - $2.25 Million	-226,100 Reduced 10.0%	2,034,552 $2.44 Million
Q1 2023 May 15, 2023	BUY	$7.77 - $12.47 $17.6 Million - $28.2 Million	2,260,652 New	2,260,652 $19.8 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $8.48 $3.86 Million - $5.94 Million	700,000 Added 44.85%	2,260,652 $18.1 Million
Q2 2022 Aug 15, 2022	SELL	$2.21 - $5.56 $23,706 - $59,642	-10,727 Reduced 0.68%	1,560,652 $8.68 Million
Q3 2021 Nov 15, 2021	SELL	$13.21 - $20.91 $870,922 - $1.38 Million	-65,929 Reduced 4.03%	1,571,379 $23.5 Million
Q2 2021 Aug 17, 2021	BUY	$15.08 - $20.3 $24.7 Million - $33.2 Million	1,637,308 New	1,637,308 $25.4 Million

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samsara Bio Capital, LLC with notifications on news.